Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A series of articles that set out to explore the global distribution of infections that cause non-malarial febrile illness has been published in BMC Medicine. The series brings together the results of large-scale systematic reviews of the causes of fever in Africa, Latin America, and Southern and South-Eastern Asia, and has helped identify major knowledge gaps, geographical differences, priority areas for diagnostics research and development, and enabled the most comprehensive systematic review of literature to date.

Mother and newborn © Arne Hoel World Bank

Febrile illness is the most common reason for childhood healthcare visits globally, with hundreds of millions of cases of fever in 0 to four-year-olds presenting at health facilities every year. Historically, in malaria-endemic countries it was assumed that malaria was the cause of fever, but with the advent of rapid diagnostic tests (RDTs) for malaria, combined with intensified malaria control activities over the last decade, the incidence rate of malaria has been substantially reduced. Health workers and researchers have noted that once malaria is ruled out, it is difficult to diagnose febrile illness due to limited diagnostic tools, laboratory facilities and the scarcity of comprehensive surveillance networks in low-resource settings. Thus, patients with fever are often misdiagnosed and given inappropriate treatments, such as antibiotics in the absence of a confirmed diagnosis, which in addition to mistreating individual patients may contribute to antimicrobial resistance.

Today, the ongoing pandemic of COVID-19, a disease with a potential presentation of non-specific febrile illness, further highlights the need for accurate diagnostics, strong surveillance networks and standardized data to efficiently handle this disease alongside addressing the multitudes of causes of potentially co-existing non-malarial febrile illnesses.

In order to map the main causes of fever in all malaria-endemic regions, researchers associated with the WorldWide Antimalarial Resistance Network (WWARN); the Infectious Diseases Data Observatory (IDDO) at the University of Oxford, the Foundation for Innovative New Diagnostics (FIND), London School of Hygiene & Tropical Medicine (LSHTM), University of Otago, University of Hong Kong, Fundação Oswaldo Cruz (Fiocruz), and the MORU Tropical Health Network - Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU) and Cambodia-Oxford Medical Research Unit (COMRU) screened more than 100,000 articles published between 1980 and 2015 to provide the most comprehensive data available to date.

Read the full story on the IDDO website

Similar stories

Professors Peter Horby and Guy Thwaites recognised in Queen’s Birthday Honours

The pioneering work of members of the University of Oxford has been recognised in The Queen's Birthday Honours List. The honorands include Professor Peter Horby and six researchers that have played key roles in leading the University’s response to the Coronavirus pandemic, from the development of new vaccines to the discovery of new drug treatments. Professor Guy Thwaites is appointed a Member of the Order of the British Empire.

RECOVERY trial finds aspirin does not improve survival for patients hospitalised with COVID-19

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for patients hospitalised with COVID-19. Patients with COVID-19 are at increased risk of blood clots forming in their blood vessels, particularly in the lungs. Between November 2020 and March 2021, the RECOVERY trial included nearly 15,000 patients hospitalised with COVID-19 in an assessment of the effects of aspirin, which is widely used to reduce blood clotting in other diseases. There was no significant difference in the primary endpoint of 28-day mortality

The COVID-19 International Modelling Consortium (CoMo Consortium) enters a new phase

Created in March 2020 to assist policymakers to make use of existing evidence in mathematical and epidemiological models to inform strategies for minimising the impact of COVID-19, the CoMo Consortium brings together mathematical modellers, epidemiologists, health economists and public health experts from more than 40 countries across Africa, Asia and South and North America.

New Pandemic Sciences Centre at the University of Oxford

The University of Oxford announces the launch of a centre of global research collaboration and excellence, the Pandemic Sciences Centre. The need for partnership between academic excellence, industry and public health organisations is one of the key lessons learned from the coronavirus pandemic. This centre will unite disciplines, and sectors, to build agile, equitable partnerships that can tackle complex problems and respond to pandemic threats at any time.

RECOVERY trial named David Sackett Trial of the Year 2020

The RECOVERY trial has been named David Sackett Trial of the Year by the Society for Clinical Trials. The award was presented today at the Society for Clinical Trials’ 42nd Annual Meeting.

AMR and scrub typhus among Chiangrai Unit's research priorities

Which infections are most common in the Chiangrai region? How should we treat them and how can we improve diagnostic? Which strategies are most effective in directing antibiotic treatment? Blog by Carlo Perrone, research physician based at the Chiang Rai Clinical Research Unit in Chiangrai, Thailand.